LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Hope S. Rugo, A. Bardia, F. Marmé, J. Cortés, P. Schmid, D. Loirat, Olivier Trédan, E.M. Ciruelos, F. Dalenc, P. Gomez Pardo, K. Jhaveri, R.J. Delaney, T. Valdez, H. Wang, W. Verret, S.M. Tolaney